The effect of omalizumab on nasal allergic inflammation

Journal of Allergy and Clinical Immunology

Volumn 110, Issue 1, 2002, Pages 68-71

  Plewako, Halina ^a   Arvidsson, Monica ^a   Petruson, Karin ^a   Oancea, Iolanda ^a   Holmberg, Kenneth ^a   Ädelroth, Ellinor ^b   Gustafsson, Hans ^c   Sandström, Thomas ^b   Rak, Sabina ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c NONE

Author keywords

Allergic rhinitis; Anti IgE; Eosinophils; IgE; Nasal biopsy; Omalizumab

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL MARKER; EOSINOPHIL PEROXIDASE; IMMUNOGLOBULIN E; LIPOCALIN; OMALIZUMAB; PLACEBO; TRYPTASE INHIBITOR;

ADULT; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG USE; EOSINOPHIL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; MALE; MAST CELL; MULTICENTER STUDY; NASAL BIOPSY; NEUTROPHIL; NOSE ALLERGY; POLLEN ALLERGY; PRIORITY JOURNAL; RANDOMIZATION; RECORDING; SEASON; SERUM; STAINING; STATISTICAL SIGNIFICANCE; SYMPTOM; T LYMPHOCYTE; TISSUE;

EID: 0036968254     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.125488     Document Type: Article

References (12)

1. Bentley AM, Jacobson MR, Cumberworth V, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992; 89:877-83.
2. Durham SR, Gould HJ, Thienes CP, et al. Expression of epsilon germline gene transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. Eur J Immunol 1997;27:2899-906.
3. Ädelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106:253-9.
4. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab recluces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
5. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997;155:1828-34.
6. Frew AJ, Kay AB. The relationship between infiltrating CD4+ lymphocytes, activated eosinophils, and the magnitude of the allergen-induced late phase cutaneous reaction in man. J Immunol 1988;141:4158-64.
7. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
8. Björnsson E, Janson C, Håkansson L, Enander I, Venge P, Boman G. Eosinophil peroxidase: a new serum marker of atopy and bronchial hyper-responsiveness. Respir Med 1996;90:39-46.
9. Nielsen LP, Bjerke T. Christensen MB, et al. Eosinophil markers in seasonal allergic rhinitis. Intranasal fluticasone propionate inhibits local and systemic increases during the pollen season. Allergy 1998;53:778-85.
10. Rak S, Löwhagen O, Venge P. The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen allergic patients. J Allergy Clin Immunol 1988;82:470-80.
11. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995;107:308-12.
12. MacGlashan DW, Bochner BS, Adelman DC, et al. Downregulation of FcεRI expression on human basophiles during in vivo treatment of atopic patients with antiIgE antibody. J Immunol 1997;158:1438-45.